RNAi specialist Dicerna begins clinical trial; Injectable eye medication launches in U.S.;

> RNAi specialist Dicerna Pharmaceuticals ($DRNA) announced that the first patient has been dosed in the Phase Ib/II clinical trial of its candidate for advanced hepatocellular carcinoma (liver cancer). Release

> pSivida ($PSDV) announced that nationwide shipments of its Iluvien injectable, sustained release micro-insert for the eye condition diabetic macular edema will commence on Feb. 23. The product is licensed to Alimera Sciences. Release

> University of North Carolina spin-off Spyryx Biosciences says it is developing a promising inhaled peptide replacement therapy to help cystic fibrosis patients clear mucus from their lungs. More | More

> The FDA approved the new 0.025 mg/day dosage of the Minivelle estradiol transdermal system for the treatment of postmenopausal osteoporosis. Manufacturer Noven Therapeutics says the medication is the world's smallest estrogen therapy patch. More